



## ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

December 30, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 30, 2020-- [ImmunoGen Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 39<sup>th</sup> Annual J.P. Morgan Virtual Healthcare Conference. The presentation is scheduled for 10:50am ET on January 13, 2021.

Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen's management team for a question-and-answer session at 11:10am ET.

A webcast of the presentation and question-and-answer session will be accessible live through the "Investors & Media" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay will be available in the same location.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20201230005005/en/>

### INVESTOR RELATIONS AND MEDIA

ImmunoGen  
Courtney O'Konek  
781-895-0600

[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

### OR

FTI Consulting  
Robert Stanislaro  
212-850-5657

[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen